Daytrana Patch Legal News Articles & Interviews

Washington, DC: Side effects involving Daytrana skin color loss isn’t the only problem the Daytrana ADHD patch has encountered over its history. In fact, while the US Food and Drug Administration (FDA) was busy compiling adverse event reports involving loss of skin pigmentation associated with the patch application, the makers and marketers of Daytrana were having other problems, prompting some critics to call for a ban of the product.

Washington, DC: Parents constantly have to make decisions about the health and well-being of their children, and sometimes those decisions involve medications that are supposed to help their children. One such medication is the Daytrana patch, which has come under scrutiny for reportedly causing a permanent loss of skin color. Of course, when parents make decisions about the best medications for their children, they do so hoping they have the best information available. Problems arise, however, when the information they have isn’t as reliable as it could be.

Miami, FL: A “Form 483” is a document issued under the auspices of the US Food and Drug Administration (FDA) over suspected lapses in quality control. In this case, the FDA wrote up Noven Pharmaceuticals for lapses in batch reviews and testing, stability and process controls, and complaints handling. Pundits are left wondering if such lapses have anything to do with Daytrana skin color loss.

New York, NY: Patients who use Daytrana have been told to watch for Daytrana side effects, including discoloration of the skin. Skin discoloration, which is not dangerous but can be permanent, has been linked to the use of the Daytrana patch, used to treat attention deficit hyperactivity disorder (ADHD). According to the US Food and Drug Administration (FDA), 51 cases of skin color loss have been reported in connection with the Daytrana patch. But back in 2013, the Institute for Safe Medicine Practices (ISMP) was questioning the continued use of Daytrana, based on repeated recalls of the drug.

Washington, DC: A rare but serious side effect involving Daytrana (methylphenidate) for treatment of ADHD is enough of an issue to cause the US Food and Drug Administration (FDA) to reference Daytrana skin color loss in a recent communication to the health and medical community. But as potentially serious as leukoderma can be, not to mention the fact that it likely is permanent, patients and consumers would have a hard time finding any reference to leukoderma on the official Daytrana website.

Washington, DC The US Food and Drug Administration (FDA) has issued a warning that Daytrana side effects could include a risk of permanent skin disfiguration. The warning came in June 2015, when the FDA said it had received 51 cases of chemical leukoderma - changing of skin color - in the past eight years.

Washington, DC Anyone who has suffered the disfigurement to the skin that stems from Daytrana side effects would be forgiven for wondering why Daytrana skin color loss was not picked up in whichever clinical trials would have been performed before the Daytrana skin patch was approved.

Washington, DC If there’s one thing about the pharmaceutical industry that stands the test of time, it is the prevailing wind of surprise that never ceases to blow as new threats from seemingly safe prescription drugs emerge and stoke the fears of patients and the consuming public. To that end, Daytrana side effects are beginning to gain a profile for all the wrong reasons.